{
    "clinical_study": {
        "@rank": "149922", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and\n      either kill them or deliver tumor-killing substances to them without harming normal cells.\n      Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more\n      sensitive to the drug.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab\n      ozogamicin in treating older patients who have relapsed acute myeloid leukemia."
        }, 
        "brief_title": "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "May 2006", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the complete response rate of elderly patients with relapsed CD33-positive\n           acute myeloid leukemia treated with oblimersen and gemtuzumab ozogamicin.\n\n        -  Determine the overall response rate and duration of response of patients treated with\n           this regimen.\n\n        -  Determine the safety of this regimen in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oblimersen IV continuously on days 1-7 and 15-22 and gemtuzumab ozogamicin\n      IV over 2 hours on days 4 and 18.\n\n      Patients are followed monthly for 6 months.\n\n      PROJECTED ACCRUAL: A total of 20-100 patients will be accrued for this study within 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed CD33+ acute myeloid leukemia (AML)\n\n               -  In first relapse from chemotherapy\n\n               -  Complete response lasting at least 3 months before relapse\n\n          -  No CNS leukemia\n\n          -  No secondary leukemia or history of antecedent hematologic disorder prior to initial\n             onset of AML (e.g., myelodysplasia)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  60 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC less than 30,000/mm^3\n\n          -  No bleeding or coagulation disorder except disease-related disseminated intravascular\n             coagulation\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  PT and PTT no greater than 1.5 times upper limit of normal OR\n\n          -  INR no greater than 1.3\n\n          -  No history of chronic hepatitis or cirrhosis\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No uncontrolled congestive heart failure\n\n          -  No New York Heart Association class III or IV heart disease\n\n        Pulmonary:\n\n          -  No severe pulmonary disease\n\n        Other:\n\n          -  HIV negative\n\n          -  No other concurrent medical disease that would preclude study entry\n\n          -  No known hypersensitivity to phosphorothioate-containing oligonucleotides, gemtuzumab\n             ozogamicin or any of its components, E. coli protein, or any product produced in E.\n             coli\n\n          -  No other concurrent malignancy\n\n          -  No known human anti-human antibodies\n\n          -  No uncontrolled seizure disorder\n\n          -  No active uncontrolled infection\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior allogeneic or autologous stem cell transplantation\n\n          -  No prior therapy with an anti-CD33 antibody (e.g., gemtuzumab ozogamicin or M195)\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 2 weeks since prior cancer chemotherapy except intrathecal chemotherapy or\n             hydroxyurea\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 2 weeks since prior systemic radiotherapy\n\n        Surgery:\n\n          -  At least 2 weeks since prior major surgery\n\n          -  No prior organ allograft\n\n        Other:\n\n          -  At least 3 weeks since prior antileukemic therapy and recovered\n\n          -  No other concurrent investigational therapy\n\n          -  No concurrent immunosuppressive therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "firstreceived_date": "June 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00017589", 
            "org_study_id": "CDR0000068721", 
            "secondary_id": [
                "GENTA-GA210", 
                "UCCRC-10928"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "oblimersen sodium", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "gemtuzumab ozogamicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemtuzumab"
        }, 
        "keyword": "recurrent adult acute myeloid leukemia", 
        "lastchanged_date": "January 3, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/GENTA-GA210"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Berkeley Heights", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07922"
                }, 
                "name": "Genta Incorporated"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia", 
        "overall_official": {
            "affiliation": "Genta Incorporated", 
            "last_name": "Stanley R. Frankel, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00017589"
        }, 
        "results_reference": {
            "PMID": "16730060", 
            "citation": "Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul;30(7):777-83. Epub 2006 May 26."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genta Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2003"
    }, 
    "geocoordinates": {
        "Genta Incorporated": "40.681 -74.431"
    }
}